CS Paper Radar

From Mutation to Medication: Characterizing Failures of Clinical LLMs to Respect Genomic Resistance

Negin Ashrafi, Roxana Daneshjou

cs.AI cs.LGq-bio.GN ·submitted 2026-11-14 11:26 UTC · v1
top venue

Abstract

Language models are increasingly proposed to support molecular tumour boards, but may recommend cancer therapies despite genomic evidence of resistance. We evaluated ten models on 1,464 resistance cases from five curated oncology knowledge bases, collecting 58,910 judgments. Models endorsed resisted therapies in 21.8-81.4% of cases. However, raw rates can reflect a tendency to agree rather than an ability to distinguish resistance from drug sensitivity: one open-weight model endorsed 81.4% of resistance cases and 82.3% of sensitivity controls. We therefore compared endorsement within matched gene and evidence-level groups. This analysis is exploratory because it was specified after the pre-registered analysis, which yielded null-to-weak results. Measured failures depended strongly on the reference knowledge base and evidence strength. When a second source independently confirmed resistance, four models across three vendors endorsed at most 2.4% of cases; at weaker evidence tiers, discrimination was not measurable. Models sometimes acknowledged resistance yet recommended the therapy. Repeating a model's own resistance conclusion reduced endorsement to 0.0-3.5% on cases where it had stated resistance. Falsely attributing the opposite conclusion increased endorsement above baseline for all seven hosted models, reaching 95.2% for GPT-4o; an instruction without an attributed conclusion changed endorsement by only 0.9 percentage points. Providing the correct curated evidence reduced unqualified strong recommendations to 0.3-3.5%, testing evidence use under an oracle condition rather than retrieval.

Comment
Accepted for publication in the Proceedings of the Machine Learning for Health (ML4H) 2026 Symposium

Closest papers

Nearest neighbours by meaning across the whole index.

OpenMTB-Audit: Exposing Over-Refusal and Clinical Expert Perspectives in LLM-Based Molecular Tumor Board Safety Evaluation

cs.AI cs.LG ·2026-10-01 ·Negin Ashrafi, Jia Luo, Stacey M. Frumm, Roxana Daneshjou
publishedbenchmarkcode/data similarity 0.65
Abstract · Accepted for oral presentation and publication at the Pacific Symposium on Biocomputing (PSB) 2027

Molecular tumor boards integrate genomic findings, clinical context, and therapeutic evidence to support precision oncology. As AI enters this workflow, a key safety challenge is distinguishing truly unsupported recommendations from evidence-supported options that still require oncologist review because of incomplete information, poor ECOG performance status, or other clinical caveats. We introduce OpenMTB-Audit, an open-source benchmark of 500 synthetic non-small cell lung cancer cases spanning five adversarial error categories and four safety labels: Supported, Partially Supported, Unsupported, and Insufficient Information. Across eight large language model configurations, we identify pervasive over-refusal: all LLM configurations failed to retain the Partially Supported label in 83.3-100% of true Partially Supported cases, achieving high aggregate safety scores through label collapse rather than clinically calibrated reasoning. To address this limitation, we developed MTB-AuditAgent, a deterministic seven-module framework separating evidence verification, missing-information detection, safety classification, and abstention. It reduces over-refusal to 6.7% and achieves 91.2% accuracy (95% CI: 88.6-93.6%). A two-oncologist annotation study found disagreement concentrated at the boundary between information sufficiency and treatment optimization, underscoring the need to preserve clinically meaningful distinctions.

0.57

Scaling large language model-assisted line-of-therapy adjudication with human-in-the-loop evidence-calibrated selection

cs.LG q-bio.QMstat.AP ·2026-11-15 ·Olatunji Oni, Sanhita Sengupta, Marc De Benedetti, Nathanial Eddy
similarity 0.63
Abstract · 12 pages, 4 figures

Large language models (LLMs) have enabled the ability to scale clinical adjudication tasks traditionally dependent on exhaustive manual review. Line-of-therapy (LoT) adjudication, a major bottleneck in oncology cohort construction, is a prime example. Line boundaries must be inferred from longitudinal treatment histories according to nuanced, study-specific definitions, at every regimen transition for every patient. LLMs can apply this adjudication at scale, but their reliability varies across patients. Treatment histories differ in complexity, and ambiguous or atypical patterns depend on expert clinical judgment. Reliable automation thus requires verified support for model assignments and the ability to identify cases that warrant manual review. Here, we present evidence-calibrated selection (ECS), a human-in-the-loop framework for scaling LLM-assisted LoT adjudication. ECS derives confidence from observed clinician adjudications, prioritizes patients with the least-supported assignments for follow-up review, and returns completed adjudications to the model as precedent. As the evidence base grows, ECS continuously calibrates confidence to estimate residual error, thus enabling more efficient use of clinician time. In simulations on 136 clinician adjudicated patients with multiple myeloma, ECS achieved a residual error of 5% after review of 44.6% of patients, compared to 62.2% when review was directed by LLM self-reported confidence and 81.9% under random sampling. These results support a scalable approach to study-specific LoT adjudication, using clinician evidence to inform automated predictions, minimize error, and reduce review burden.

0.21

LABEL: Literature Asymmetry between Efficacy and Limits in Drug Knowledge and Language Models

cs.AI cs.IR ·2026-11-14 ·S M Rayeed, Charles V. Stewart, Yao Ma
code/datahot direction similarity 0.60
Abstract · 27 pages (9 main + supplementary material), 8 figures, 7 tables

Every medication comes with two types of medical facts: indications, which describe what conditions the drug treats (benefits), and contraindications, which describe who must avoid it to prevent serious harm (safety limits). Although contraindications are critical for patient safety and FDA regulations require listing them as rigorously as indications, we find that contraindications are far less documented than indications in general prose. In this paper, we measure how often these texts contain both facts across 574 drugs from PrimeKG by comparing a drug's indications against its own contraindications. Across Wikipedia articles and PubMed abstracts, we find that reference prose names a drug's benefits about twice as often as its safety limits (within-drug odds ratio 2.19). We call this documentation gap LABEL (Literature Asymmetry between Efficacy and Limits). Language models mirror this gap. As we scale Qwen2.5 from 0.5B to 14B, accuracy on indications rises by 18.3 points, whereas accuracy on contraindications remains flat near random guessing. However, when we provide models with a retrieved passage that states the answer, they use safety facts just as effectively as benefits. Furthermore, routing safety questions to official FDA labels boosts accuracy by 15.8 points whenever the label states the fact. Overall, our findings show that models fail on medication safety not because they cannot reason about risk, but because free-text corpora lack safety facts. Clinical AI systems should therefore route medication-safety questions to official regulatory labels and structured databases rather than relying on general public records. Code and data are available at https://github.com/SMRayeed/LABEL.

0.42

Large language models show systematic failures in incorporating evolving medical knowledge

cs.AI ·2026-10-22 ·Min Zeng, Zaifu Zhan, Kai Yu, Rui Zhang
similarity 0.60
Abstract

Medical knowledge evolves, yet whether large language models (LLMs) faithfully incorporate revisions into clinical recommendations remains unclear. We introduce ChronoEvo, comprising 1,709 recommendation-level revisions across 12 forms of medical knowledge change and 275 guideline lineages, to distinguish recognition of revised guidance from its full incorporation. With updated guideline evidence explicitly provided, revision recognition exceeded full incorporation across 14 models, with a 20.1-percentage-point gap in the strongest model. For Qwen3-4B, 90.8% of responses recognized revisions, 80.2% were clinically correct, and 58.5% fully incorporated them, yielding a 32.3-percentage-point gap. Two clinicians' adjudicated assessment of 300 responses yielded a 40.3-percentage-point gap in this enriched validation sample; 61 of 144 responses with incomplete incorporation were clinically incorrect. Prompting Qwen3-4B to prioritize revised evidence reduced outdated-content retention and improved clinical correctness without significantly improving full incorporation. These findings identify faithful incorporation of revised guidance as a distinct challenge for clinical LLM reliability.

0.17

Advancing Clinical Trial Outcome Prediction with Domain-Specific Large Language Models

cs.AI ·2026-10-30 ·Burak Bakkar, Hana Moalla, Mohamed Salem Jedidi, Haifa Ben Messaoud, Nicolas Lopez Carranza
benchmark similarity 0.59
Abstract

Clinical trial failures are a major barrier to efficient drug development, incurring substantial costs and delaying patient access to effective therapies. Structured approaches such as the Hierarchical Interaction Network (HINT) predict trial outcomes by explicitly modelling interactions between drugs, diseases and protocols, but make limited use of the free text in trial registrations. We evaluate two domain-specific language models, BioBERT (108M parameters) and BioMistral (7B parameters), for phase-level outcome prediction on the TOP benchmark (12,477 trials), representing each trial as text built from ten ClinicalTrials.gov fields. We compare fine-tuning (full fine-tuning for BioBERT, low-rank adaptation for BioMistral) with probing, in which the pretrained model is frozen and only a lightweight classifier is trained on its embeddings. On the held-out test set of each phase, all four language-model variants achieved higher ROC-AUC (0.613--0.772) and PR-AUC (0.649--0.901) than the published HINT results, corresponding to relative PR-AUC gains of 10--20\%. F1 differences were small and mixed, and no model, including HINT, clearly exceeded the F1 of a trivial classifier that predicts success for every trial. Under the configurations tested, probing performed comparably to fine-tuning: fine-tuned models scored highest on ROC-AUC and PR-AUC in Phases I and II, and frozen BioMistral embeddings in Phase III (ROC-AUC 0.772; PR-AUC 0.901), although most differences between variants were below 0.03 and were not tested for significance. These results suggest that pretrained biomedical representations already encode signal relevant to trial outcome, and that probing is a computationally cheaper alternative to fine-tuning for this task.

0.22

Answering clinicians' questions over trial evidence tables with verifiable, feedback-driven language models

cs.AI ·2026-10-01 ·Manan Roy Choudhury, Suparno Roy Chowdhury, Swastik Sahoo, Muhammad Ali Khan, Kaneez Zahra Rubab Khakwani +3 more
published similarity 0.59
Abstract

Systematic reviews condense clinical trials into evidence tables, yet clinicians can interrogate these tables only through database queries, and many questions concern attributes that the table does not record, such as a drug's target class or a harmonised endpoint. Here we introduce FD-SCoPE, a language-model framework that answers both kinds of question, exposes the query, the selected trials and the derivation rule behind every answer, and learns from expert corrections. On an oncology evidence table of 159 immune checkpoint inhibitor trial records, FD-SCoPE completed all 140 clinician-style tasks (alternatives, 90.7-97.9%). For questions needing derived attributes it retrieved 99.3% of relevant trial records at a positive predictive value of 89.8% and outperformed four alternative approaches (derived-value F1 77.7% versus 64.8-73.4%). Corrections on 299 questions, simulated from reference answers, raised F1 on 1,201 unseen questions from 77.9% to 84.9%. Language models coupled with executable queries, verified programs and expert feedback can give clinicians auditable access to trial evidence.

0.32

When to Stop Asking: Factor Coverage Bias and LLM Determinability Judgments with Underspecified Information in Medicine

cs.AI ·2026-10-19 ·Yusuke Watanabe, Yohei Kobashi, Taisei Tosaki, Takeshi Kojima, Yusuke Iwasawa +2 more
benchmark similarity 0.57
Abstract · 17 pages, 8 figures, 8 tables

Clinical decision-making often begins with underspecified information and requires not only gathering missing information but also knowing when to stop. This calls for judging determinability (whether the available information is sufficient for a decision) by considering whether missing information could change the conclusion, not simply the amount of available decision-relevant information. Reliance on this amount as a cue for determinability, which we term \textit{factor coverage bias}, could undermine the trustworthiness of large language models (LLMs) through premature conclusions or excessive information gathering, such as unnecessary invasive tests. Yet whether LLMs exhibit this bias remains insufficiently studied. To address this gap, we construct a controlled pairwise benchmark in which LLMs identify the determinable case within each determinable--undeterminable pair. We add a decision-relevant factor to either side while keeping each case's determinability unchanged, and similarly add irrelevant text to distinguish this bias from context-length effects. Adding a relevant factor made LLMs more likely to select the augmented case as determinable even when it remained undeterminable, an effect that persisted with increased reasoning effort, while adding irrelevant text made them less likely to select the augmented case, an effect that reasoning substantially reduced. These findings identify factor coverage bias as a failure mode distinct from context-length effects and a potential risk to LLM trustworthiness. Our work provides an evaluation framework for LLM trustworthiness under underspecification.

0.29

A Semantic Model of Genetic Evidence: A Step Toward Bridging the Basic-Science-Clinic Gap

cs.DB cs.AIq-bio.GN ·2026-09-03 ·Michael Bouzinier, Dmitry Etin
benchmarkpositioncode/data similarity 0.57
Abstract · 16 pages; supplementary material (32 pages) included in this submission. Schema, annotations, and code: https://github.com/ForomePlatform/ge…

Scientific and clinical decision-making depends on evidence from the primary literature, but existing standards for representing that evidence (FHIR Evidence, ECO, SEPIO, and the GA4GH Genomic Knowledge Standards) are oriented toward clinical-trial workflows, evidence codes, or single-variant assertions, and do not capture the fine-grained, domain-specific structure of claims in basic and pre-clinical research. We introduce a semantic model for scientific evidence with three core classes, specialize it for genetics, align it structurally to FHIR Evidence with a SEPIO-anchored credibility decomposition, and attach a compact dimensional vocabulary whose conditional-activation rules are validated by a SHACL schema for the implemented constraints. Using clinical variant interpretation as the driving use case, we evaluate the model through a human-AI annotation pilot over six genetics papers, yielding 28 evidence items and 95 source-anchored assertions, with a workflow that keeps curator-authored reference annotations distinct from AI-drafted annotations. Treating the pilot as a feasibility study rather than a benchmark, we argue that the model is a useful increment toward trustworthy, AI-ready infrastructure for variant interpretation: a reference data model and validation schema for representing genetic evidence.

0.31